FDA approves AstraZeneca's Baxfendy, an aldosterone synthase inhibitor for uncontrolled hypertension
Baxdrostat lowered systolic pressure by a placebo-adjusted 9.8 mmHg in patients already taking at least two antihypertensives including a diuretic, targeting the aldosterone pathway behind much of resistant hypertension.